The best way to judge a product is by sales numbers and customer...

The best way to judge a product is by sales numbers and customer testimonials. When a customer such as AstraZeneca orders more after the initial purchase then we can assume that the product meets at least the minimum expectations. As soon as a second Big Pharma signs a contract the market won't have any excuse for doubting the quality.

But then it depends on management to make the most of it. Having the best product in the market doesn't automatically means sales will go through the roof. IPD for example got a worldwide monopoly for its product and yet sales are slow due to health insurers coming to the party at a speed slower than " Continental Drift ". No problems with insurers for CC5 but there are always unexpected obstacles that got put in companies' ways when rolling out a superior product.

At least, in contrast to OCC, no hype or inflated market cap here. That's the old-fashioned way I like, sp increases based on actual sales figures and not on baseless hype. I rather accumulate an undervalued stock which has a high chance to explode than an overhyped stock that has a high chance to implode when actual figures won't match expectations.

GLTA